| Abstrakt: |
A recent study conducted by researchers at the College of Medicine in Ha'il, Saudi Arabia, focused on identifying biomarkers for predicting the response to Trastuzumab in HER2-positive Metastatic Breast Cancer (HER2-MBC) patients. The study involved 40 patients with HER2-MBC, and the expression levels of miR-200c-3p and the FOXP3 gene were assessed in plasma samples before and after Trastuzumab therapy. The findings suggest that low plasma expression levels of miR-200c-3p may serve as a promising biomarker for predicting the response to Trastuzumab in HER2-MBC patients. [Extracted from the article] |
